Several brokerages have updated their recommendations and price targets on shares of Cronos Group (NASDAQ: CRON) in the last few weeks:

  • 8/12/2019 – Cronos Group is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $18.00 price target on the stock.
  • 8/12/2019 – Cronos Group was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cronos Group, Inc. engages in the investment in firms which are licensed to produce and sell medical marijuana. Its portfolio includes In The Zone, Peace Naturals, Whistler Medical Marijuana Co., ABcann, Hydropothecary, Vert Medical and Evergreen Medicinal Supply. Cronos Group Inc., formerly known as PharmaCan Capital Corp., is headquartered in Toronto, Canada. “
  • 8/9/2019 – Cronos Group had its “sell” rating reaffirmed by analysts at BMO Capital Markets.
  • 8/9/2019 – Cronos Group was upgraded by analysts at Canaccord Genuity from a “sell” rating to a “hold” rating. They now have a $17.00 price target on the stock, up previously from $16.00.
  • 8/9/2019 – Cronos Group had its price target raised by analysts at Bank of America Corp from $20.00 to $26.00. They now have a “buy” rating on the stock.
  • 8/9/2019 – Cronos Group was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “Cronos Group, Inc. engages in the investment in firms which are licensed to produce and sell medical marijuana. Its portfolio includes In The Zone, Peace Naturals, Whistler Medical Marijuana Co., ABcann, Hydropothecary, Vert Medical and Evergreen Medicinal Supply. Cronos Group Inc., formerly known as PharmaCan Capital Corp., is headquartered in Toronto, Canada. “
  • 8/1/2019 – Cronos Group was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 7/10/2019 – Cronos Group was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cronos Group, Inc. engages in the investment in firms which are licensed to produce and sell medical marijuana. Its portfolio includes In The Zone, Peace Naturals, Whistler Medical Marijuana Co., ABcann, Hydropothecary, Vert Medical and Evergreen Medicinal Supply. Cronos Group Inc., formerly known as PharmaCan Capital Corp., is headquartered in Toronto, Canada. “
  • 7/2/2019 – Cronos Group was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Cronos Group, Inc. engages in the investment in firms which are licensed to produce and sell medical marijuana. Its portfolio includes In The Zone, Peace Naturals, Whistler Medical Marijuana Co., ABcann, Hydropothecary, Vert Medical and Evergreen Medicinal Supply. Cronos Group Inc., formerly known as PharmaCan Capital Corp., is headquartered in Toronto, Canada. “
  • 6/28/2019 – Cronos Group is now covered by analysts at Consumer Edge. They set an “equal weight” rating on the stock.

NASDAQ:CRON traded up $0.13 on Wednesday, hitting $11.88. The company had a trading volume of 2,573,140 shares, compared to its average volume of 4,850,474. The stock has a market capitalization of $3.99 billion, a price-to-earnings ratio of -148.50 and a beta of 3.43. The firm has a 50 day moving average of $14.21 and a two-hundred day moving average of $17.04. Cronos Group Inc has a 52 week low of $6.50 and a 52 week high of $25.10.

Cronos Group (NASDAQ:CRON) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. The business had revenue of $10.80 million during the quarter, compared to the consensus estimate of $7.16 million. Cronos Group had a net margin of 2,521.25% and a return on equity of 60.20%. The company’s revenue was up 217.6% on a year-over-year basis. As a group, equities analysts expect that Cronos Group Inc will post -0.07 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new stake in Cronos Group during the fourth quarter valued at about $56,000. Millennium Management LLC grew its position in Cronos Group by 161.9% during the fourth quarter. Millennium Management LLC now owns 92,706 shares of the company’s stock valued at $963,000 after acquiring an additional 242,406 shares during the period. Pennsylvania Trust Co purchased a new stake in shares of Cronos Group in the first quarter worth about $6,838,000. Gulf International Bank UK Ltd purchased a new stake in shares of Cronos Group in the first quarter worth about $61,000. Finally, Hudock Capital Group LLC boosted its position in shares of Cronos Group by 8,816.0% in the first quarter. Hudock Capital Group LLC now owns 2,229 shares of the company’s stock worth $41,000 after buying an additional 2,204 shares during the period. 8.16% of the stock is owned by hedge funds and other institutional investors.

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada.

Featured Story: Why does a company issue an IPO?

Receive News & Ratings for Cronos Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.